Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery

Overview

Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.

Interventions

• Device Surgery with ELIOS laser
  This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these micr

Primary outcome measures

• Intraocular pressure (IOP) [Time frame: day 0, 7 and 30, and month 3, 6 and 12 months after surgery]

Secondary outcome measures (1)

• Quality of life [Time frame: before and after surgery (1, 3, 6 and 12 months)]

Eligibility criteria

Inclusion criteria

• Patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form
• Visually significant cataract with indication for surgery
• Primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery.
• Open iridocorneal angle (Shaffer classification grade 2-4)
• Early to moderate glaucoma (advanced glaucoma, with MD from VFs worse than -12dB, will be excluded)

Exclusion criteria

• Presence of severe systemic pathologies 2024-A01891-46\_Protocol\_V6\_21112024\_Elios Page 20 / 58
• Pregnant or breastfeeding women
• <18 years of age
• Presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye.
• History of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery
• Visual acuity worse than "counting fingers".
• Closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris.
• Normal-pressure glaucoma
• Pachymetry < 490 um or > 620 μm
• Glaucomatous visual field with mean deviation worse than ≤-12 dB
• IOP > 35 mmHg
• Autoimmune disorder, especially collagenosis
• Patient under protective supervision
• Patient not covered by a social security scheme

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

France · 1 center

• Hôpital Privé de la Baie — Avranches

Identifiers

NCT: NCT06760169 · 2024-32-PDB

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗